ABSTRACT Background: Epidemiologic data suggest that diet is a risk factor in the etiology of gastric cancer. However, the role of dietary fatty acids, a modifiable risk factor, remains relatively unexplored. Objective: The objective of this study was to determine the association of plasma phospholipid fatty acid concentrations, as biomarkers of exogenous and endogenously derived fatty acids, with the risk of gastric adenocarcinoma in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition-Europe Gastric Cancer (EPIC-EURGAST). Design: Fatty acids were measured by gas chromatography in prediagnostic plasma phospholipids from 238 cases matched to 626 controls by age, sex, study center, and date of blood donation. Conditional logistic regression models adjusted for Helicobacter pylori infection status, BMI, smoking, physical activity, education, and energy intake were used to estimate relative cancer risks. Results: Positive risk associations for gastric cancer were observed in the highest compared with the lowest quartiles of plasma oleic acid (OR: 1.72; 95% CI: 1.01, 2.94), di-homo-c-linolenic acid (OR: 1.92; 95% CI: 1.10, 3.35), a-linolenic acid (OR: 3.20; 95% CI: 1.70, 6.06), and the ratio of MUFAs to saturated fatty acids, as an indicator of stearoyl-CoA desaturase-1 enzyme activity (OR: 1.40; 95% CI: 0.81, 2.43). An inverse risk association was observed with the ratio of linoleic to a-linolenic acid (OR: 0.37; 95% CI: 0.20, 0.66). Conclusion: These data suggest that a specific prediagnostic plasma phospholipid fatty acid profile, characterized mainly by high concentrations of oleic acid, a-linolenic acid, and di-homo-c-linolenic acid, which presumably reflect both a complex dietary pattern and altered fatty acid metabolism, may be related to increased gastric cancer risk.
INTRODUCTION

GC
4 presents wide international variation in incidence rates (1) , which indicates that environmental and lifestyle factors, particularly diet, likely play an important role in its etiology (2) . Previous epidemiologic studies have shown that high intakes of fruit and vegetables are negatively associated with GC risk (3) (4) (5) (6) , with stronger support for this association coming from case-control studies than from cohort studies (7) . In contrast, a high intake of salt (5, 8) and of meats and meat products (3, 4, 9-11) has usually been linked to increased risk. Endogenous formation of nitroso compounds may account for the positive association reported between red and processed meat consumption and noncardia GC risk (12) .
Previous research relating dietary fat and different subtypes of dietary fat, as major dietary components, to GC has been relatively scarce, especially in prospective settings. High intakes of saturated (13, 14) and monounsaturated (13) fat have been associated with an increased risk of GC in case-control studies, whereas one case-control study reported a decreased risk of GC associated with a high intake of linoleic acid (15) .
Estimation of dietary fatty acid intakes is prone to many measurement errors. The conversion of food items into their fatty acid content is exceptionally complex for numerous reasons, including the variation in fatty acid composition within the same food according to cooking methods and industry supply. In contrast, biomarkers of dietary fatty acids, such as adipose tissue triglyceride and plasma or erythrocyte phospholipid fatty acid concentrations, offer objective, quantitative measures of bioavailable amounts of these nutrients irrespective of the source and quality of food, particularly for fatty acids that are not endogenously synthesized (16, 17) . Thus, the use of biological markers of fat intake and fatty acid metabolism is a more meaningful approach for investigating the association between exogenous and endogenously produced fatty acids and cancer risk.
We determined the association of prediagnostic plasma phospholipid fatty acid concentrations with GC risk in a casecontrol study nested within EPIC-a large cohort of .520,000 subjects from 10 European countries (18, 19) . In addition, because GC risk factors may differ on the basis of histologic subtype or the anatomic localization within the stomach (20) , the effects of plasma fatty acids by GC subtype and subsites were also considered, as were Helicobacter pylori infection status and presence of SCAG status.
SUBJECTS AND METHODS
Details on the study population, blood sample collection procedures, follow-up methods, ascertainment of vital status, selection of study subjects, diet and lifestyle questions, nested case-control study design, and laboratory methods for H. pylori analysis are detailed elsewhere (9, 21, 22) .
Study subjects, data and biosample collection, and follow-up
The EPIC cohort consists of 23 subcohorts in 10 European countries (Denmark, France, Greece, Germany, Italy, the Netherlands, Norway, Spain, Sweden, and United Kingdom), with a total of 521,468 subjects enrolled. The French and Norwegian cohorts, and the Naples center of Italy and the Utrecht center in the Netherlands, consist of women only. Usual diet over the previous 12 mo was measured at recruitment by using validated country-specific diet questionnaires. Values for total energy intake and macro-and micronutrients were computed by using country-specific food-composition tables. Standardized lifestyle and personal questionnaires, various anthropometric measures, and blood samples were collected from most participants (1992-1998). Eligible participants gave written informed consent. Approval for this study was obtained from the ethical review boards of the IARC and from all local participating centers.
At each center, blood samples were drawn from participants and stored at 5-10°C, protected from light, and transported to local laboratories to be processed and portioned into aliquots (19, 23) . The only exceptions were the Oxford center, where blood samples were collected from a network of general practitioners and transported to a central laboratory by post, and centers in Sweden and Denmark, where blood was portioned into aliquots within 1 h of being drawn. In all countries, blood was separated into fractions (serum, plasma, red blood cells, and buffy coat). In each country, except Denmark and Sweden, each fraction was placed into straws, which were heat-sealed and stored in liquid nitrogenNorway were not included in the current analysis because of the low number of GC cases and short period of follow-up.
To reduce the effects of extreme intakes, subjects in the top and bottom 1% of the ratio of energy intake to estimated energy requirement (calculated from age, sex, height, and body weight) and subjects with previous cancer diagnoses or with missing dietary data were excluded (18 cases), as were 138 prevalent GC cases.
Nested case-control analysis and selection of study subjects A total of 238 gastric cancer cases (n = 133 men and 105 women) with available blood samples were identified and matched to 626 controls (n = 333 men and 293 women). For each identified GC case, incidence density sampling was used to identify control subjects (1:4) matched by sex, age group (6 2.5 y), study center, and date of blood sample collection (6 45 d). GC cases in the nested case-control design were also subdivided by anatomic subsite (tumors originating from the gastric cardia, n = 69; noncardial tumors, n = 124; and tumors from unknown sites, n = 45) and by histologic subtype (diffuse tumors, n = 91; intestinal tumors, n = 94). The remaining cases (n = 53) were of unknown or mixed histologic types.
Analysis of plasma phospholipid fatty acids
Plasma phospholipid fatty acids were analyzed in the same laboratory at the IARC by using a method that was previously described (24) . Briefly, lipids were extracted from 200 lL plasma, phospholipids were purified by solid-phase extraction, and fatty acid methyl esters were formed by transmethylation of the phospholipids and analyzed by gas chromatography on a 30-m polar column. Cases and controls were run in the same batch. One quality-control sample originating from a standard plasma pool, located in the middle and end of the batch, was injected twice within each batch. CVs for the major fatty acids ranged from 0.93% for large peaks to 12.75% for the smallest peaks.
The relative amount of each fatty acid, expressed as a percentage of total fatty acids, was quantified by integrating the area under the peak and dividing the result by the total area. Values for the individual fatty acids were used to calculate the percentage of main fatty acid groupings: SFAs, cis MUFAs, n26 PUFAs, and n23 PUFA. In addition, we also determined the DIs as the ratios of MUFAs to SFAs (DI n29; an indicator of activity of the ratelimiting enzyme D
9
-desaturase or SCD-1, which transforms palmitic and stearic acids into the MUFAs palmitoleic and oleic acids), c-linolenic acid to linoleic acid (DI n26; an indicator of activity of D 6 -desaturase), and arachidonic acid to di-homoc-linolenic acid (DI n25; an indicator of activity of D
5
-desaturase) (Figure 1) . The ratios of n26 to n23 PUFAs and of linoleic acid to a-linolenic acid indicate the activities of the 2 parallel fatty acid metabolic pathways that compete for the desaturase and elongase enzymes.
Laboratory assay, H. pylori infection, and SCAG status The method used to determine H. pylori infection status was detailed elsewhere (21) . The analysis for H. pylori infection status (quantification of anti-H. pylori and anti-CagA IgG antibodies) were assessed for 238 cases and their 626 matched controls in our study. Quantification of anti-H. pylori antibodies in plasma samples was done by ELISA using incubation with lysates of the CCUG H. pylori strain. PGA was assayed in plasma samples by using a commercial microplate-based quantitative ELISA kit (Biohit). SCAG was serologically defined as a circulating PGA concentration ,22 lg/L (21).
Statistical methods
Differences in mean fatty acids between cases and controls were tested by paired t tests of the log-transformed value in each casecontrol set. ORs and 95% CIs for GC risk in relation to each plasma individual fatty acid and fatty acid groupings were calculated by conditional logistic regression (version 9; SAS statistical software), stratified by the case-control set. Plasma phospholipid fatty acids were divided into quartiles based on the distribution among controls. Multivariate analyses were run with control for potential confounders, including H. pylori infection status (yes or no); BMI (in quartiles); status, duration, and intensity of smoking (never smokers, ex-smokers who smoked for ,10 y, ex-smokers who smoked for 10 y, smokers who smoke ,15 cigarettes/d, smokers who smoke between 15 and 25 cigarettes/d, smokers who smoke 25 cigarettes/d, or missing); physical activity (at work and leisure expressed as metabolic equivalent tasks); level of schooling (unspecified/none/primary school, technical/professional school, secondary school, or university degree; proxy variable for socioeconomic status); and energy intake (in quartiles). The effect of alcohol or meat intake was also examined. Because it did not substantially change the risk estimates, it was not included in the final model. For all models, linear trend tests were determined by using a score variable with values from 1 to 4, consistent with the quartile grouping.
Subgroup analyses were performed by unconditional logistic regression, including matching variables in the model, according to sex, European region [north-central Europe (Sweden, Denmark, Germany, the Netherlands, United Kingdom, and France) compared with southern Europe (Italy, Greece, and Spain], SCAG status [yes (PGA 22 lg/L) compared with no (PGA . 22 lg/L)], H. pylori status (infection or no infection), and time from blood donation to cancer diagnosis (,2 y compared with 2 y). Tests for heterogeneity were performed by using chi-square tests. Because only 20% of cases and 8% of controls had SCAG, which resulted in small numbers of subjects in each quartile in this subgroup analyses, we performed an exact test to get unbiased estimates of the P value to evaluate relative risks in subgroups of SCAG. This allows a more accurate estimation of model parameters, CIs, and associated P values when the sample size is limited.
We also investigated associations with different outcome types: anatomic subsite (cardia compared with noncardia) and histologic subtype (diffuse compared with intestinal). GC that could not be classified by anatomical subsite or histologic subtype were excluded in those subanalyses. Tests for heterogeneity were also performed by using chi-square tests.
RESULTS
Description of the study population
Baseline characteristics and a description of the study population are shown in Table 1 . A total of 238 GC cases and 626 matched controls with available blood samples were identified. On average, GC cases had 3.2 y between blood donation and the time of diagnosis and had a higher percentage of H. pylori and SCAG positivity than did controls.
Mean plasma phospholipid fatty acid concentrations in case and control subjects in the EPIC-EURGAST Study
The means (6SDs) of the percentage of plasma individual fatty acids and groupings for case and control subjects are shown in Table 2 . In both cases and controls, SFA represented ;40% of total fatty acids, MUFAs ;12.5%, n26 PUFAs ;39%, and n23 PUFAs ;7%; trans MUFAs quantified are mainly represented by elaidic acid.
For plasma individual fatty acids, the mean concentration of oleicacid was significantly higherincases thanin controls.For fatty acid groupings, only the mean total plasma MUFA concentration was significantly higher in cases than in controls (Table 2) .
Plasma phospholipid fatty acid concentrations and gastric cancer risk in the EPIC-EURGAST study
The ORs for GCs according to quartiles of plasma total and individual fatty acids and the ratios of fatty acids are shown in Table 3 . No significant associations were apparent for any category of SFA, n26 PUFA, or n23 PUFA. However, for MUFA, a dose response increase in risk was observed, which was statistically significant at the highest quartile of plasma concentration (OR top compared with bottom quartile: 1.75; 95% CI: 1.04, 2.95; P-trend = 0.017).
For individual MUFAs, an increased risk of GC was associated with an increasing concentration of oleic acid (OR of top compared with bottom quartile: 1.72; 95% CI: 1.01, 2.94; P-trend = 0.047). Although GC risk appeared to be higher with increasing concentrations of elaidic acid, the association was not statistically significant (OR top compared with bottom quartile: 1.63; 95% CI: 0.89, 2.97; P-trend = 0.122). Of the n26 PUFAs, a positive association was found between di-homo-c-linolenic acid and GC risk (OR top compared with bottom quartile: 1.92; 95% CI: 1.10, 3.35; P-trend = 0.03). Of the n23 PUFAs, a positive association was found between a-linolenic acid and GC risk (OR top compared with bottom quartile: 3.20, 95% CI: 1.70, 6.06; P-trend = 0.001). Longchain n23 PUFAs were not significantly associated with GC risk.
Considering the ratios of fatty acids, a positive association was found between GC risk and the ratio of MUFA to SFA (DI n29) (OR top compared with bottom quartile: 1.40; 95% CI: 0.81, 2.43; P-trend = 0.053). No significant association was found between GC risk and the ratio of c-linolenic acid to linoleic acid (DI n26) (OR top compared with bottom quartile: 1.56; 95% CI: 0.95, 2.56; P-trend = 0.235) nor with the ratio of arachidonic acid to di-homo-c-linolenic acid (DI n25) (OR top compared with bottom quartile: 0.67; 95% CI: 0.42, 1.06; P-trend = 0.109). Finally, a negative association was found between the ratio of linoleic acid to a-linolenic acid and GC risk (OR top compared with bottom quartile: 0.37; 95% CI: 0.20, 0.66; P-trend = 0.002) ( Table 3) .
No significant GC risk associations were found for any of the individual plasma fatty acids and groupings by anatomic subsite (P-heterogeneity: SFA, 0.12; MUFA, 0.49; n26 PUFA, 0.71; n23 PUFA, 0.68), histologic subtype (P-heterogeneity: SFA, 0.78; MUFA, 0.50; n26 PUFA, 0.59; n23 PUFA, 0.95), or sex (P-heterogeneity: SFA, 0.97; MUFA, 0.91; n26 PUFA, 0.69; n23 PUFA, 0.34) (data not tabulated).
Consideration of H. pylori infection status showed a positive statistically significant GC risk association in H. pylori-positive subjects (n = 199 cases and 416 controls) with MUFA concentration (OR of top compared with bottom quartile: 1.95; 95% CI: 1.08, 3.52; P-trend = 0.02), although P-heterogeneity for the effect between H. pylori-positive and -negative subjects was not significant (P = 0.34). The effect for MUFA was likely due to oleic acid (OR of top compared with bottom quartile: 2.08; 95% CI: 1.13, 3.83; P-trend = 0.03). Associations between individual SFAs, n26 PUFAs, or n23 PUFAs and GC risk did not differ between H. pylori-positive and H. pylori-negative subjects (data not tabulated).
Analyses by European region showed that the positive association between oleic acid and GC risk tended to be more pronounced in the north-central region than in the south, although the P value for heterogeneity was not significant (P = 0.58) (data not tabulated). The positive association between di-homo-c-linolenic acid (P-heterogeneity = 0.04) or a-linolenic acid (P-heterogeneity = 0.31) and GC risk was stronger in the south than in the north-central region (data not tabulated).
Because the main source of oleic acid and a-linolenic acid in north-central Europe is meat intake, we further analyzed the associations between these specific fatty acids and GC risk separately in the north-central and southern regions, with further adjustment for meat intake. However, this did not change the risk estimates (data not tabulated). The potential effect modification by the time to diagnosis of GC of ,2 y or .2 y showed no overall significant heterogeneity (data not tabulated). The potential effect modification by SCAG status showed no significant heterogeneity for the association between di-homo-c-linolenic acid (P = 0.28) or a-linolenic (P = 0.15) acid and GC risk (data not tabulated).
DISCUSSION
In this nested case-control study based on the prospective EPIC cohort, we found evidence of increased GC risk associated with increasing concentrations of oleic acid, di-homo-c-linolenic acid, and a-linolenic acid. The ratio of MUFA to SFA, as a putative index of activity of SCD-1, was positively associated with GC risk.
Grouping of individual fatty acids into their main families showed no statistically significant associations with GC risk, except for MUFA, increased concentrations of which were strongly associated with higher risk. This association was largely related to oleic acid, the main dietary MUFA. Oleic acid is not an essential fatty acid and can be either derived from the diet or formed endogenously by the desaturation of stearic acid into oleic acid via the microsomal enzyme SCD-1. Dietary MUFAs originated mainly from olive oil in southern Europe and from meat in north-central Europe (25) . However, in a cross-sectional study within the EPIC cohort, the weak correlations calculated at the individual level between plasma phospholipid oleic acid and olive oil or meat intake suggested that dietary contributors of plasma oleic acid concentrations may not be strong determinants compared with endogenous hepatic synthesis, mainly in countries with low olive intake (16) . Thus, an increased risk of GC associated with a high level of oleic acid along with a high ratio of MUFAs to SFAs, as previously reported in GC (26) and breast cancer (24, 27, 28) , might be mostly related to increased desaturation of stearic acid into oleic acid rather than to a diet rich in MUFAs. Diet may also have an important effect on SCD-1 activity. In EPIC, a high consumption of alcohol was associated with increased ratio of MUFA to SFA, whereas a high consumption of olive oil counteracted this effect (16, 29) . These data suggested that high plasma phospholipid oleic acid, presumably reflecting both a specific complex dietary pattern and increased stearic acid desaturation via SCD-1, is related to increased risk of GC.
The potential pathway underlying the association between an increased prediagnostic plasma MUFA to SFA ratio and increased risk of cancer is not known. Despite the overactivation of enzymes that synthesize SFAs (30) , abundant amounts of MUFAs are found in cancer cells (31, 32) . It is known that MUFAs can serve as mediators of signal transduction and cellular differentiation, and unbalanced concentrations of these mediators have also been implicated in carcinogenesis (33) . The expression of SCD-1, the main SCD isoform in humans, is elevated in several human cancers and chemically induced tumors (31, 34, 35) . The suppression of SCD-1 expression reduces cancer cell proliferation and in vitro invasiveness and dramatically impairs tumor formation and growth (36, 37) . These data may suggest that endogenously synthesized MUFAs, rather than exogenous MUFAs, act as regulators of cancer cell growth (38) . Another MUFA that deserves attention with respect to cancer risk is elaidic acid, the prevailing trans MUFA isomer occurring during partial hydrogenation of vegetable oils and used as ingredient in the formulation of industrial processed foods (39) . Only a few studies have examined the association between industrial trans fatty acid intake and cancer risk, but most of them reported evidence of increased risks of breast cancer (27, 40) , distal colorectal cancer (41) , and prostate cancer (42) associated with increasing concentrations of industrially produced trans fatty acids. Here, we also found a suggestion of a positive association between GC risk and plasma phospholipid elaidic acid concentrations. The lack of a significant association may be explained by the fact that the laboratory method used a 30-m column, which was nonspecific for the separation of cis-from trans fatty acids, hence not allowing complete separation of elaidic acid from oleic acid.
The 2 PUFA subtypes may lead to production of different eicosanoid families, which have vastly different inflammatory effects in various tissues, including those of the stomach. Inflammation, particularly due to H. pylori infection, is a major gastric risk factor, and increased expression of cyclooxygenase-2, key regulator of prostaglandin metabolism, has been suggested to be an early event in GC (43) . The end products of cyclooxygenase-2 activity consist of a panel of prostaglandins and thromboxanes, which are critical regulators of fundamental physiologic and pathologic processes, including platelet aggregation, T cell development, inflammation, and cancer (44) . Indeed, use of nonsteroidal antiinflammatory medications that inhibit cyclooxgenase-2 have been suggested to decrease GC risk (45) . In the current study, a higher concentration of di-homoc-linolenic acid was associated with an increased GC risk, as previously reported in prostate cancer, particularly advanced tumors (46) . The main dietary sources of di-homo-c-linolenic acid are oil seeds, such as borage, evening primrose, and black currant oils, but its blood concentrations are likely mostly due to its synthesis from the metabolism of linoleic acid via D 6 -desaturation and elongation (16, 29) . This could explain the apparently discrepant findings regarding the association between high borage oil consumption and decreased GC risk (47) . However, we found no significant association between risk of GC and the ratio of c-linolenic acid to linoleic acid, as an index of D
6
-desaturase activity, or with the ratio of arachidonic acid to di-homo-c-linolenic acid, as an index of D
5
-desaturase. The current study showed a strong association between an increased risk of GC and increasing concentrations of a-linolenic acid-the essential fatty acid of the n23 series. a-Linolenic acid is present in flaxseed oil, some vegetable and nut oils, and animal fats. Several epidemiologic studies have reported strong associations between high dietary intake or blood concentrations of a-linolenic acid and increased risks of breast (48) , colorectal (49) , and prostate (50-52) Cancers. In these studies, adjustment for animal or nonanimal sources did not change the cancer risk estimates for a-linolenic acid. However, a study reported decreased breast cancer risk associated with a high consumption of a-linolenic acid from fruit and vegetables and an increased risk associated with high consumption of a-linolenic acid from nut mixes and processed meat (53) . Because a-linolenic acid is preferentially oxidized among PUFAs, an alternative hypothesis might be that lower oxidation of a-linolenic acid is associated with higher GC risk. Further studies are required to determine whether altered metabolism of a-linolenic acid has a mechanistic role in GC etiology or whether this fatty acid is a biomarker of a specific food pattern that may affect differentially the risk of this cancer.
Even if a strength of this study is the measurement of the plasma concentration of fatty acids in a subset of cases from which blood samples were collected before cancer diagnosis, the possibility that prediagnostic SCAG may have affected absorption and metabolism of fatty acids (reverse causation), because it was the case for vitamins B-6 and riboflavin (54) , cannot be ruled out, despite the absence of statistical heterogeneity by time since diagnosis and SCAG status. Finally, we cannot exclude results due to chance alone because of the high number of tests performed.
In summary, findings from this study suggest that a prediagnostic plasma phospholipid fatty acid profile characterized mainly by high concentrations of oleic acid, a-linolenic acid, and di-homo-c-linolenic acid-which presumably reflects both a complex dietary pattern and impaired metabolism-is associated with an increased risk of GC.
